Why the study?
Betablocker use in Takotsubo syndrome is controversial, and the effect of preadmission betablocker use on adverse cardiovascular events has not been studied.
Does preadmission betablocker therapy increase adverse cardiovascular events in patients hospitalized for Takotsubo syndrome?
Population
56 patients hospitalized for TTS between April 2017 and July 2021
Comparison
Preadmission betablocker therapy vs no preadmission betablocker therapy
Follow-up
During hospitalization
Authors
Loading...
May warrant caution with preadmission betablockers in TTS; leaves open causality and need for prospective trials.
Does preadmission betablocker therapy increase adverse cardiovascular events in patients hospitalized for Takotsubo syndrome?
Preadmission betablocker therapy in patients with Takotsubo syndrome is associated with a 4.5-fold increased risk of in-hospital adverse cardiac events, particularly cardiac decompensation.
Topf et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: